↓ Skip to main content

Dove Medical Press

Article Metrics

Impact of potential inappropriate NSAIDs use in chronic pain

Overview of attention for article published in Drug Design, Development and Therapy, April 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
6 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
80 Mendeley
Title
Impact of potential inappropriate NSAIDs use in chronic pain
Published in
Drug Design, Development and Therapy, April 2015
DOI 10.2147/dddt.s80686
Pubmed ID
Authors

Silvia Ussai, Luca Miceli, Federica Pisa, Rym Bednarova, Riccardo Petelin, Giorgio Della Rocca, Antonio Giordano

Abstract

Pain remains one of the main reasons for medical consultation worldwide: moderate- to severe-intensity pain occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for long-term use and a careful surveillance to monitor for toxicity and efficacy is critical. This study aims to assess: 1) the pattern of use of NSAIDs and opioids in a population covered by a cloud-based pharmacovigilance surveillance system; and 2) potential inappropriate use. A retrospective 18-months systematic analysis on patients' pain treatment was performed. The primary endpoint was evaluating the prevalence of NSAIDs and opioids use and the duration of therapy regimen. The secondary endpoint was to investigate the prevalence of NSAIDs taken for >21 consecutive days concomitant with drugs for peptic ulcer and gastroesophageal reflux disease (GORD) or antiplatelet drugs. The yearly cost for individual users of concomitant NSAIDs for more than 21 consecutive days and of GORD medications has been estimated. A total of 3,050 subjects with chronic pain were enrolled; 97% of them took NSAIDs for >21 consecutive days; about one-fourth of these users also received drugs for peptic ulcer and GORD (Anatomical Therapeutic Chemical code A02B). The yearly cost foran individual who uses NSAIDs for >21 consecutive days as well as concomitant GORD medications is 61.23 euros. In total, 238 subjects (8%) using NSAIDs for >21 days also received one antiplatelet agent. About 11% of subjects received opioids at least once and only 2% of them carried on the therapy for more than 90 consecutive days. In evaluating the escalation in dosage as a proxy of dependence risk, this study shows no dosage escalation in our cohort of chronic pain population - that is to say we show no risk of dependence.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Italy 1 1%
Australia 1 1%
Unknown 77 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 20%
Student > Master 15 19%
Student > Ph. D. Student 11 14%
Researcher 10 13%
Other 5 6%
Other 10 13%
Unknown 13 16%
Readers by discipline Count As %
Medicine and Dentistry 26 33%
Nursing and Health Professions 11 14%
Pharmacology, Toxicology and Pharmaceutical Science 9 11%
Agricultural and Biological Sciences 4 5%
Biochemistry, Genetics and Molecular Biology 4 5%
Other 9 11%
Unknown 17 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2016.
All research outputs
#6,767,274
of 13,431,750 outputs
Outputs from Drug Design, Development and Therapy
#290
of 1,408 outputs
Outputs of similar age
#79,046
of 228,643 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 61 outputs
Altmetric has tracked 13,431,750 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,408 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,643 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.